Akers Biosciences (AKER) 4.61 $AKER Akers Announces

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2015 at 9:23 PM

Akers Biosciences (AKER) 4.61 $AKER

Akers Announces Conference Call to Discuss Its Fourth Quarter and Full Year 2014 Earnings
GlobeNewswire - Thu Mar 19, 6:00AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"

, a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, announces that the Company will publish earnings for the 2014 fiscal year end on Monday, March 23, 2015.
AKER: 4.61 (+0.26)

4 Stocks Under $10 to Trade for Big Breakouts
at The Street - Tue Mar 10, 1:01PM CDT
These under-$10 stocks are within range of triggering breakout trades.
MNGA: 0.86 (+0.06), AKER: 4.61 (+0.26), PRAN: 1.15 (-0.08), XOMA: 3.99 (-0.15)

Akers Biosciences May Turn Around in Q4 on Solid Top Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:21AM CST
Akers Biosciences Inc (AKER) is expected to report fourth-quarter 2014 figures on Feb 19, 2015.
IPXL: 46.34 (-0.47), ISIS: 73.59 (-3.49), BEAT: 10.16 (-0.14), AKER: 4.61 (+0.26)

Akers' Management System Certified to ISO 13485 (2003)
GlobeNewswire - Mon Feb 09, 6:18AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"

, a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that the Company's Management System has been certified by SAI Global, a leading global management systems Certification Body, to ISO 13485 (the "Certification"

. The Certification is a requirement in certain countries to enable regulatory approval of medical devices.
AKER: 4.61 (+0.26)

Akers Presenting at US Investor Conference
GlobeNewswire - Thu Feb 05, 12:06PM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"

, a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, will present to prospective investors next week at the 17 Annual BIO CEO & Investor Conference in New York City.
AKER: 4.61 (+0.26)

Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 49.03 (-0.41), AKER: 4.61 (+0.26), AKBA: 12.46 (-0.54), AGIO: 107.97 (-2.99), AMRI: 18.80 (-0.14)

European Patent Granted for Akers' Rapid Blood Separation Technology
GlobeNewswire - Mon Jan 26, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "Akers"

, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that the European Patent Office has issued a patent surrounding the Company's novel blood separator technology and method of separating a fluid fraction from whole blood (the "Technology"

. Akers was granted U.S. patent protection for the Technology in 2011.
AKER: 4.61 (+0.26)

Akers Expands U.S. Sales Efforts With Key Leadership Additions
GlobeNewswire - Tue Jan 20, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"

, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the recruitment and deployment of a full-time, pan-U.S. sales and marketing team under the direction of the newly appointed Executive Vice President, Sales and Marketing, John C. Cheneval.
JNJ: 102.40 (+0.71), AKER: 4.61 (+0.26), NVS: 101.68 (+1.81)

Dave Gentry Interviews Akers Biosciences' Founder Dr. Ray Akers
GlobeNewswire - Mon Jan 05, 9:22AM CST
RedChip Companies, Inc. ("RedChip"

, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"

TM) television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (Nasdaq:AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity.
AKER: 4.61 (+0.26)

Bright Outlook and New Products on the Way Prompt Analyst Report of Akers Bioscience Issued by BrokerBank Securities
PR Newswire - Fri Jan 02, 6:00AM CST
Akers Bioscience Inc. (NASDAQ: AKER) has seen its shares reach new December highs on the sales success and news of the PIFA Heparin/PF4 Rapid Assay product line beginning distribution in Europe. The product line has been very successful in the US and is projected to generate significantly more revenue for the company in the upcoming year.
AKER: 4.61 (+0.26)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 12:03PM CST

IHT: 2.64 (unch), NES: 3.26 (+0.26), VJET: 7.75 (-0.29), AHC: 8.31 (+0.12), OSGB: 4.25 (+0.15), SYNC: 2.53 (+0.05), SYRX: 1.23 (+0.03), JOB: 0.92 (-0.04), LIVE: 2.99 (+0.02), PME: 2.41 (unch), ATOS: 1.97 (+0.01), BWEN: 4.75 (-0.27), KEG: 1.83 (+0.16), AKER: 4.61 (+0.26), XONE: 13.72 (-0.38), MCHX: 4.48 (+0.05), SPP: 1.71 (-0.01), RTGN: 4.10 (+0.08)

Akers Biosciences Signs European Distribution Agreements for PIFA Heparin PF4 Rapid Assay Products
GlobeNewswire - Thu Dec 18, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"

, a leading designer and manufacturer of rapid diagnostic screening and testing products, has entered into its first European distribution agreements since the installment of its international vice president in August 2014. The Company has entered into multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products with Cryopep SARL, covering France, Belgium, the Netherlands and Luxembourg; and DiaLine AG, covering Switzerland and Lichtenstein.
AKER: 4.61 (+0.26)

Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip"

, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"

TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.65 (+0.01), ATNM: 2.87 (+0.08), AKER: 4.61 (+0.26), CGIX: 7.85 (-0.11)

Akers Biosciences Announces $1 Million Initial Order to Supply PIFA Heparin/PF4 Products to China
GlobeNewswire - Wed Dec 10, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"

, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order"

valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek"

to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China"

.
AKER: 4.61 (+0.26)

Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST

XBI: 233.86 (-4.12), AKER: 4.61 (+0.26), AEZS: 0.60 (+0.03)

Cannabis (MMJ) Breathalyzer Could Follow Vertical Path of Alcohol Breathalyzer
ACCESSWIRE - Tue Dec 02, 8:40AM CST
Whitefish, MT / ACCESSWIRE / December 2, 2014 / The effects of alcohol on a driver are well documented, with motor skills and often decision-making skills decreasing with each drink, subsequently increasing the likelihood of a fatal accident. A field sobriety test (i.e. walking heel-to-toe, follow a pen with eyes, stand on one foot) typically does an ample job at helping police officers identify a driver under the influence of alcohol, which is then typically followed by the tried-and-true alcohol breathalyzer test to pinpoint blood alcohol concentration (BAC). Although some laws and penalties vary from state to state, there is a nationwide standard of drunk driving being defined as BAC at or above 0.08 percent. Technological advancements have made alcohol breathalyzers affordably available to businesses and consumers, like Akers Biosciences' (NASDAQ: AKER) CHUBE and BreathScan products, to estimate BAC. Another portable BAC estimator, Breathometer's eponymous device that operates by attaching it to the audio output of a smart phone, garnered an aggregate $1 million in investments from all five "sharks" in April on the popular CNBC show "Shark Tank," lending to the idea that it is a growing industry against the backdrop of stiffening laws and greater awareness. Breathometer isn't alone in the smart phone breathalyzer space, orders are being taken for FLOOME, a universal smartphone accessory for measuring BAC developed with the help of Proto Labs (NYSE: PRLB).
PRLB: 70.00 (+0.68), AKER: 4.61 (+0.26)

Horrendous Stock Performance Of RedChip Nation Healthcare And Biotech Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 01, 10:29AM CST

INO: 9.09 (-0.36), AKER: 4.61 (+0.26)

RedChip Issues Research Update on Akers Biosciences
GlobeNewswire - Tue Nov 18, 7:40AM CST
RedChip Companies, Inc., today announced it has issued a research update on Akers Biosciences Inc. (Nasdaq:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products.
AKER: 4.61 (+0.26)

Akers Biosciences Net Loss of $1.12M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:18AM CST

AKER: 4.61 (+0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

2026 Diamond Certified Directory: A Trustworthy Guide

A Refreshing Reality in a Sea of Online Reviews Imagine having a compass that actually points you in the right direction through the foggy mess of online reviews. That's what the Fall 2026 Diamond Certified Directory aims to be. This ain't some random collection of opinions. This is hard-hitting, reliable information that's been battle-tested in the real world. We're...

BETR Faces Shareholder Suit After Plummeting Stock

Better Home & Finance Navigates Turbulent Waters Not every day the news comes up smelling of roses, and that's putting it lightly for Better Home & Finance, trading as NASDAQ: BETR. When you're talking about a splash that sends shockwaves, losing over 28% of your stock value on a single trading day is one whale of a splash indeed. The Numbers That Shook the Waters It's no...

Latham & Watkins Welcomes Privacy Sledgehammer Macko

Privacy Enforcer Lands at Latham & Watkins With regulatory pressure turning up the heat, Latham & Watkins has roped in Michael Macko, a seasoned pro when it comes to privacy enforcement. To give you a peek into his credibility, Macko doesn't just have a foot in the door—he built the doorframe himself over at the California Privacy Protection Agency (CalPrivacy)....

SLM Hit by Earnings Miss: Shareholders Eye Legal Action

When A Profit Turns To Loss There's a certain sting that comes with expecting a profit only to get smacked with a loss. You know the kind—like when SLM Corporation shareholders had their expectations shattered on October 22, 2026. They figured they'd see a $0.17 profit per share, but what landed instead was a $0.19 loss. That's a $0.36-per-share swing, enough to make...

Fair Play in Focus: SYNA, CSR, VCTR, EFSI Deals Scrutinized

The Corporate Buzz: Deals Under the Microscope Riding the rollercoaster of mergers and acquisitions ain't new in the stock market realm. But when the stakes seem one-sided, alarms start ringing. Halper Sadeh LLC, a firm that cuts its teeth on this kind of corporate sleuthing, is all hands on deck probing a slew of big deals involving Synaptics (NASDAQ:SYNA), Centerspace...

CPSC's Management Overhaul: Progress or Just Polishing?

The Tangled Web of Bureaucracy Ah, the Consumer Product Safety Commission—CPSC for short. It's like the Secretariat of product safety, but often knee-deep in old problems. Over the years, hearing about their challenges is like flipping through a well-worn playbook. But now, the talk is all about a fresh page under Acting Chairman Peter A. Feldman. The watchdog in...

111, Inc. Strategizes with Advisors Amid Proposal Talks

Every time a company's board starts tossing around phrases like "strategic alternatives," you’ve got to pay closer attention. 111, Inc., holding the NASDAQ ticker YI, is one such entity at a crossroads. They've enlisted Houlihan Lokey China Limited as their independent financial advisor and Kirkland & Ellis as their U.S. legal counsel to sift through potential strategic...

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Better Home & Finance Faces 28.5% Stock Plunge, Lawsuit

The Sudden Dive in Better Home's Stock Imagine cruising down the highway with the wind in your hair and suddenly slamming into a pothole. That's the kind of jarring experience Better Home & Finance Holding Company (NASDAQ: BETR) investors felt when the stock took a nosedive, diving a hefty 28.5%. Back on May 7, 2026, the company released financial figures that flipped the...